ARMATA PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Payments to Acquire Debt Securities, Available-for-sale of $3.39 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-19.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2020-03-19
- ARMATA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2018-12-31 was $0.00.
- ARMATA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2018-09-30 was $0.00.
- ARMATA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2018 was $3.39M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $0.00 derived: sum of 2 quarters · filed 2020-03-19 | $3.39M 10-K · filed 2020-03-19 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $3.39M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $3.39M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |